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ABSTRACT
The disposition of cefpirome after single intramuscular (i.m.) administration (10 mg.kg-1) was investigated 
in fi ve male cross-bred calves and in vitro plasma protein binding was determined. The concentration of cefpirome 
in the plasma was estimated by the microbiological assay technique. Binding of cefpirome to plasma proteins 
was determined at different concentration levels by the equilibrium dialysis technique. The peak plasma level 
of cefpirome after i.m. administration to cattle was attained at 45 min post-dose and the drug was detected in 
plasma above MIC of 0.5 μg.mL-1 for up to 10 h. The drug disposition followed a one-compartment open model. 
The values of t1/2Ka, t1/2β and AUC were 0.21 ± 0.01 h, 2.06 ± 0.02 h and 31.7 ± 0.95 μg.mL
-1.h, respectively. 
Cefpirome was bound to the plasma proteins to the extent of 26.0 ± 2.84 percent at the concentration range of 
1-100 μg.mL-1. The binding capacity of cefpirome to plasma proteins and the dissociation rate constant of the 
protein-drug complex were 3.71 ×10-8 ± 0.31 ×10-8 mole.g-1 and 3.43 ×10-7 ± 0.46 ×10-7 mole, respectively. 
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Introduction
Cephalosporins are among the most widely used group of antibacterials in veterinary 
and human medical practice. Cefpirome, a new fourth generation cephalosporin, possesses 
an extended spectrum of activity against resistant organisms such as Pseudomonas 
spp. (SULTANA and ARAYNE, 2007; OZBEK and OTUK, 2010). It is commonly used in 
humans to treat bacterial meningitis and infections of the lower respiratory tract, skin and 
urinary tract (PRESCOTT, 2006). Cefpirome has the clinical advantage of being highly 
stable to hydrolysis by several β-lactamases including Amp C β-lactamases that confer 
resistance to a wide variety of β-lactam antibiotics and, therefore, it is clinically useful 
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against organisms producing Amp C-type β-lactamases (PRESCOTT, 2006; AHMED and 
SHIMAMOTO, 2008). In view of the species variation in the disposition kinetic data of 
antimicrobials, it is considered important to investigate the disposition kinetics of drugs 
in different animal species and under different environmental conditions. The disposition 
kinetics of cefpirome have been described in rabbits (MRESTANI et al., 2003), rats (ISERT et 
al., 1992), dogs (ISERT et al., 1992; KITA et al., 1992), monkeys (KLESEL and SEEGER, 1983), 
buffalo calves (RAJPUT et al., 2007a,b; RAJPUT et al., 2008) and humans (SAUERMANN et 
al., 2005). It has been emphasized that the pharmacokinetic data of a drug generated in one 
species cannot be extrapolated to other species. Since there is no information available on 
the pharmacokinetic behaviour of cefpirome in cross-bred calves, the present study was 
undertaken to investigate the disposition kinetics after single intramuscular administration 
and in vitro plasma protein binding of cefpirome in cross-bred calves.
Materials and methods 
Experimental animals and drug administration. The study was conducted on fi ve 
healthy male cross-bred calves between 6-12 months of age and weighing 80-120 kg. 
The animals were dewormed and kept under observation for 2 weeks of acclimatization 
before commencement of the experiment. During the experimental period, the animals 
were maintained on concentrate feed and were allowed to graze freely. Water was 
provided ad libitum. The average daily temperature in the shed was about 25 °C during 
the experimental period. The experimental protocol followed the ethical guidelines on 
the proper care and use of animals and was approved by the Institutional Animal Ethics 
Committee. Cefpirome (Cepirom, Orchid Chemicals and Pharmaceuticals Ltd, India) was 
administered by a single intramuscular (i.m.) injection into the lateral neck region at the 
dose rate of 10 mg.kg-1. 
Sample collection. Blood samples (6 mL) were collected into heparinized glass 
centrifuge tubes by jugular venipuncture at time intervals of 1, 2.5, 5, 7.5, 10, 15, 30, 45 
min and 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 14 and 24 h of administration of cefpirome. 
Plasma was separated and stored at -20 °C until analyzed for cefpirome, which was 
usually done on the next day after collection.
Analytical method. The concentration of cefpirome in plasma was estimated by the 
microbiological assay technique (ARRET et al., 1971) using Escherichia coli (microbial 
type culture collection; MTCC 739) as the test organism, as detailed in previously 
published reports (RAJPUT et al., 2007b). This method detected both the parent compound 
and its active metabolites. The assay could detect a minimum of 0.05 μg.mL-1 of the 
antimicrobial active compound. 
Pharmacokinetic analysis. The concentrations of cefpirome in the plasma were plotted 
on a semi-logarithmic scale as a function of time and the pharmacokinetic parameters were 
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calculated manually for each animal by the least square regression technique (GIBALDI 
and PERRIER, 1982). 
Plasma protein binding. In vitro binding of cefpirome to plasma proteins was 
determined by employing the equilibrium dialysis technique (KUNIN et al., 1959). Various 
concentrations of cefpirome (1, 10, 20, 50 and 100 μg.mL-1) were prepared in plasma 
taken from untreated cattle. Each dialyzing bag fi lled with 5 mL of plasma, containing 
a known amount of the drug, was then immersed in separate tubes containing 5 mL of 
phosphate buffer and the tubes were incubated at 37 °C for 24 h with occasional shaking. 
At the end of the incubation period, the buffer as well as the contents of the dialysing 
bags, were analyzed separately for the concentration of cefpirome. For each concentration 
three separate sets of experiments were conducted. The extent of in vitro plasma protein 
binding of cefpirome was calculated by the equation: 
           
CP’ - CB
 Percent of cefpirome bound to plasma protein =       × 100
                
CP
Where, CP’ is the concentration of cefpirome in the plasma after incubation, CB is 
the concentration of cefpirome in the phosphate buffer after incubation and CP is the 
concentration of cefpirome in the plasma before incubation. The constants for binding of 
cefpirome to plasma proteins were obtained as described by PILLOUD (1973) to describe 
the capacity and nature of the binding characteristics of the drug. 
Results
The plasma levels of cefpirome at different time intervals are presented in Fig. 
1. The plasma concentration of cefpirome at 1 min after a single i.m. injection was 
0.31 ± 0.01 μg.mL-1, and it gradually increased until the peak plasma concentration 
(10.1 ± 0.05 μg.mL-1) was observed at 45 min. The pharmacokinetic parameters that 
described the absorption and elimination pattern of cefpirome were calculated and are 
presented in Table 1. Table 2 summarizes the parameters of in vitro plasma protein 
binding of cefpirome.
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Table 1. Disposition kinetic parameters of cefpirome in cross-bred claves (n = 5) after a single 
intramuscular dose of 10 mg.kg-1 body weight
Parameter
Animal number
Mean ± SE1 2 3 4 5
A’ (μg.mL-1) 14.4 12.8 13.7 12.7 12.2 13.1 ± 0.40
B (μg.mL-1) 13.2 11.6 12.6 11.2 11.2 12.0 ± 0.39
Ka (h-1) 3.09 3.40 3.13 3.77 3.19 3.32 ± 0.13
β (h-1) 0.33 0.34 0.35 0.33 0.33 0.34 ± 0.01
t½Ka (h) 0.22 0.20 0.22 0.18 0.22 0.21 ± 0.01
t1/2 β (h) 2.10 2.04 1.98 2.10 2.10 2.06 ± 0.02
AUC (μg.mL-1.h) 35.3 30.5 31.7 30.7 30.3 31.7 ± 0.95 
AUMC (μg.mL-1.h2) 119.7 99.6 101.6 102.3 102.0 105.1 ± 3.69 
MRT (h) 3.39 3.27 3.21 3.33 3.37 3.31 ± 0.03 
Cmax (μg.mL
-1) 10.1 10.1 9.98 10.2 10.3 10.1 ± 0.05
tmax (h) 0.75 0.75 0.75 0.75 0.75 0.75 ± 0.00
A’ and B, zero-time plasma concentration intercepts of regression lines of absorption and elimination phases, 
respectively; Ka and β, absorption and elimination coeffi cients, respectively, in the mono-exponential equation 
that describes the plasma concentration-versus-time data; t1/2Ka and t1/2β, half-lives of absorption and elimination 
phases, respectively; AUC, area under the plasma concentration-time-curve; AUMC, area under the fi rst moment 
of the plasma concentration-time-curve; MRT, mean residence time of drug in body; Cmax,, maximum plasma 
concentration; tmax, time required to attain peak plasma level.
Table 2. In vitro binding and kinetic constants of binding of cefpirome to plasma proteins of 
cross-bred calves (n = 5)
Exp. No.








Concentration of cefpirome (μg.mL-1)
1 10 20 50 100
1 47.0 19.1 25.2 17.6 23.8 3.96 ×10-8 4.34 ×10-7
2 48.0 17.7 22.8 18.7 25.8 4.07 ×10-8 2.98 ×10-7
3 29.0 41.9 12.2 21.7 19.7 3.09 ×10-8 2.96 ×10-7













Overall Mean ± SE of extent of binding = 26.0 ± 2.84%. 
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Fig. 1. Semilogarithmic plot of plasma concentration-time profi le of cefpirome in cross-bred 
calves following a single intramuscular dose of 10 mg.kg-1 body weight. Values given are mean ± 
SE of 5 animals. Data was analyzed according to the one-compartment open model. Absorption 
(Ka) and elimination (β) phases are represented by the least square regression lines. The 
calculated points (o) of the absorption phase were obtained by the residual method.
Discussion
The evaluation of the results on the observed plasma levels of cefpirome indicated that 
the data may be best fi tted to the one-compartment open model and the pharmacokinetics 
were described by the equation: CP = Be
-βt - A’e-kat. The mono-compartment model has 
also been used to describe the disposition pattern of cefpirome (RAJPUT et al., 2007b) 
and ceftriaxone (GOHIL et al., 2009) in buffalo calves and ceftizoxime in calves (SINGH 
et al., 2008) following single i.m. administration. The rapid attainment of peak cefpirome 
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following i.m. administration. A similar peak plasma level of cefpirome (9.04 μg.mL-1) 
was produced at 0.5 h after i.m. administration in buffalo calves (RAJPUT et al., 2007b). 
The minimum therapeutic plasma concentration of cefpirome against human pathogens 
has been reported to be 0.05-0.39 μg.mL-1 (ARAI et al., 1988) but such values for 
cefpirome have not been determined against animal isolates. Another fourth-generation 
cephalosporin, cefquinome, is active against pathogens generally found in animal 
infections and possesses a potency and spectrum comparable to cefpirome (MURPHY 
et al., 1994). The minimum inhibitory concentration (MIC90) of cefquinome against 
animal pathogens, including E. coli, Klebsiella pneumoniae, Haemophilus infl uenzae, 
Pasteurella, Salmonella and Streptococcus species, have been reported in the range of 
0.03-1.0 μg.mL-1 (AL-TAHER, 2010). In this study, a concentration of 0.5 μg.mL-1 was 
considered as the reference plasma level for cefpirome.
The study of kinetic determinants of cefpirome following i.m. administration revealed 
a low value of absorption half-life, t½ka (0.21 ± 0.01 h) in the present study, which was 
similar to the low t½ka of 0.19 h reported for cefpirome in buffalo calves (RAJPUT et 
al., 2007b), further confi rming that after i.m. administration, absorption of cefpirome is 
very rapid. Rapid absorption after i.m. injection has also been reported for cefepime and 
ceftizoxime in crossbred calves (ISMAIL, 2005; SINGH et al., 2008) and ceftriaxone in 
buffalo calves (GOHIL et al., 2009). The high values of AUC (31.7 ± 0.95 μg.mL-1.h) 
AUMC (105.1 ± 3.69 μg.mL-1.h2) in the present study were comparable to the values of 
AUC (28.7 ± 1.9 μg.mL-1.h) and AUMC (107.7 ± 6.7 μg.mL-1.h2) of cefpirome in buffalo 
calves (RAJPUT et al., 2007b). Similarly, high values of AUC have also been reported in 
dogs (103 μg.mL-1.h), rabbits (18.9 μg. min.mL-1) and man (16.5 g.min.L-1) for cefpirome 
(KITA et al., 1992; MRESTANI et al., 2003; SAUERMANN et al., 2005).
The elimination of cefpirome was rapid, with a t½β of 2.06 ± 0.02 h following i.m. 
administration in crossbred calves. Short elimination half-lives have also been reported 
for cefpirome after i.v. (2.14 h) and i.m. (2.39 h) administration and cefepime (3.0 h) 
following i.v. administration in buffalo calves (RAJPUT et al., 2007a,b; JOSHI and SHARMA, 
2009) and for ceftizoxime (1.44 h) and cefepime (3.02 h) after i.m. administration in calves 
(ISMAIL, 2005; SINGH et al., 2008). The value of MRT in crossbred calves following i.m. 
administration of cefpirome (3.31 ± 0.03 h) in the present study was in accordance with 
the values of MRT (3.76 h) observed after i.m. administration of cefpirome in buffalo 
calves (RAJPUT et al., 2007b), however it was longer than the MRT of ceftriaxone (1.55 h) 
reported after intravenous (i.v.) administration in cattle (KUMAR et al., 2010).
The extent of plasma protein binding of cefpirome varied from 12.2 to 48.0 percent 
with an overall mean of 26.0 ± 2.84 percent. The calculated values of the capacity of 
cefpirome to bind with plasma proteins of crossbred calves (βi) and the dissociation rate 
constant of protein drug complex (Kβ) were 3.71 ×10
-8 ± 0.31 ×10-8 mol.g-1 and 3.43 ×10-7 ± 
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0.46 ×10-7 mol, respectively. The binding of the drug to plasma proteins was weak and 
reversible, which was evident from the lower value of βi than the value of Kβ. These 
results are in accordance with the 30.7% binding of cefpirome to the plasma proteins 
of buffalo calves (RAJPUT et al., 2007b), however a low value of plasma protein binding 
of cefpirome has been reported at 10 percent in humans (STEINER et al., 2004) and 8.8 
percent in rats (ARAI et al., 1988). A marked inter-species difference has been reported in 
the binding of cephalosporins to plasma proteins in animals. A plasma protein binding 
study of six cephalosporins in animals revealed high protein binding in rat, monkey, and 
human plasma, whereas in dog plasma, protein binding was markedly lower (RICHTER 
et al., 1998). Similarly the plasma protein binding of cefoperazone in calves has been 
reported to be nearly one fourth of that in humans (GUPTA et al., 2008).
_______
Acknowledgements
The fi nancial assistance received by the senior author from Guru Angad Dev Veterinary and Animal Sciences 
University, in the form of a University Merit Scholarship to pursue the present study, is duly acknowledged.
References
AHMED, A. M., T. SHIMAMOTO (2008): Emergence of a cefepime- and cefpirome-resistant 
Citrobacter freundii clinical isolate harbouring a novel chromosomally encoded AmpC β-
lactamase, CMY-37. Int. J. Antimicrob. Agents. 32, 256-261. 
AL-TAHER, A. Y. (2010): Pharmacokinetics of cefquinome in camels. J. Anim. Vet. Adv. 9, 848-
852.
ARRET, B., D. P. JOHNSON, A. KIRSHBAUM (1971): Outline of details for microbiological 
assay of antibiotics: second revision. J. Pharm. Sci. 60, 1689-1694.
ARAI, S., S. KOBAYASHI, S. HAYASHI, T. SAKAGUCHI (1988): Distribution of cefpirome (HR 
810) to exudate in the croton-oil-induced rat granuloma pouch and its therapeutic effects on 
experimental infections in the pouch. Antimicrob. Agents Chemother. 32, 1396-1399. 
GIBALDI, M., D. PERRIER (1982): Methods of residuals. In: Pharmacokinetics. 2nd ed. Marcel 
Dekker, New York. pp. 433-444.
GOHIL, P. V., U. D. PATEL, S. K. BHAVSAR, A. M. THAKER (2009): Pharmacokinetics of 
ceftriaxone in buffalo calves (Bubalus bubalis) following intravenous and intramuscular 
administration. Iranian J. Vet. Res. 10, 33-37.
GUPTA, J. K., R. K. CHAUDHARY, V. K. DUMKA (2008): Pharmacokinetics after single 
intramuscular administration and in vitro plasma protein binding of cefoperazone in cross bred 
calves. Vet. Arhiv 78, 441-448.
ISERT, D., N. KLESEL, M. LIMBERT, A. MARKUS, G. SEIBERT, E. SCHRINNER (1992): 
Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and 
dogs. J. Antimicrob. Chemother. 29, 31-37.
8 Vet. arhiv 82 (1), 1-9, 2012
N. Rajput et al.: Disposition of cefpirome in calves
ISMAIL, M. M. (2005): Disposition kinetics, bioavailability and renal clearance of cefepime in 
calves. Vet. Res. Commun. 29, 69-79. 
JOSHI, B., S. K. SHARMA (2009): The pharmacokinetics of cefepime in E. coli lipopolysaccharide 
induced febrile buffalo calves. Vet. Arhiv 79, 523-530.
KITA, Y., T. YAMAAKI, A. IMADA (1992): Comparative pharmacokinetics of SCE-2787 and 
related antibiotics in experimental animals. Antimicrob. Agents Chemother. 36, 481-486.
KLESEL, N., K. SEEGER (1983): Pharmacokinetic properties of the new cephalosporin antibiotic 
HR 810 in animals. Infection 11, 318-321.
KUMAR, S., A. K. SRIVASTAVA, V. K. DUMKA, N. KUMAR, R. K. RAINA (2010): Plasma 
pharmacokinetics and milk levels of ceftriaxone following single intravenous administration 
in healthy and endometritic cows Vet. Res. Commun. 34, 503-510.
KUNIN, C. M., R. J. DORNBUS, M. FINLAND (1959): Distribution and excretion of tetracycline 
analogies in normal young man. J. Clin. Invest. 38, 1950-1963.
MRESTANI, Y., B. BRETSCHNEIDER, A. HARTI, R. H. H. NEUBERT (2003): In-vitro and in-
vivo studies of cefpirome using bile salts as absorption enhancers. J. Pharm. Pharmacol. 55, 
1601-1606.
MURPHY, S. P., M. E. ERWIN, R. N. JONES (1994): Cefquinome (HR 111V) in vitro evaluation 
of a broad-spectrum cephalosporin indicated for infections in animals. Diag. Microbiol. Infect. 
Dis. 20, 49-55.
OZBEK, B., G. OTUK (2010): Activities of fourth generation cephalosporins alone and in 
combination with gentamicin, amikacin, ciprofl oxacin and levofl oxacin against bloodstream 
Pseudomonas aeruginosa isolates. Ind. J. Med. Microbiol. 28, 84-85.
PILLOUD, M. (1973): Pharmacokinetics, plasma protein binding and dosage of oxytetracycline in 
cattle and horses. Res. Vet. Sci. 15, 224-230.
PRESCOTT, J. F. (2006): Beta lactam antibiotics: cephalosporins. In: Antimicrobial Therapy in 
Veterinary Medicine, 4th ed. (Giguere, S., J. F. Prescott, J. D. Baggot, Eds.), Wiley-Blackwell, 
San Francisco. pp.139-158.
RAJPUT, N., V. K. DUMKA, H. S. SANDHU (2007a): Disposition kinetics and urinary excretion 
of cefpirome after intravenous injection in buffalo calves. J. Vet. Sci. 8, 21-25. 
RAJPUT, N., V. K. DUMKA, H. S. SANDHU (2007b): Pharmacokinetic disposition of cefpirome 
in buffalo calves (Bubalus bubalis) following single intramuscular administration. Iranian J. 
Vet. Res. 8, 212-217.
RAJPUT, N., V. K. DUMKA, H. S. SANDHU (2008): Infl uence of experimentally induced fever on 
the disposition of cefpirome in buffalo calves. Environ. Toxicol. Pharmacol. 26, 305-308. 
RICHTER, W. F., P. HEIZMANN, J. MEYER, V. STARKE, T. LAVE (1998): Animal 
pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl) 
cephalosporins. J. Pharm. Sci. 87, 496-500.
SAUERMANN, R., G. DELLE-KARTH, C. MARSIK, I. STEINER, M. ZEITLINGER, 
B.X. MAYER-HELM, A. GEORGOPOULOS, M. MULLER, C. JOUKHADAR (2005): 
9Vet. arhiv 82 (1), 1-9, 2012
N. Rajput et al.: Disposition of cefpirome in calves
Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of 
septic patients. Antimicrob. Agents Chemother. 49, 650-655.
SINGH, R., R. K. CHAUDHARY, V. K. DUMKA (2008): Infl uence of paracetamol on the 
pharmacokinetics and dosage regimen of ceftizoxime in cross bred calves. Israel J. Vet. Med. 
63, 72-76.
STEINER, I. M., H. LANGENBERGER, C. MARSIK, B. X. MAYER, M. FISCHER, A. 
GEORGOPOULOS, M. MÜLLER, G. HEINZ, C. JOUKHADAR (2004): Effect of 
norepinephrine on cefpirome tissue concentrations in healthy subjects. J. Antimicrob. 
Chemother. 53, 506-511.
SULTANA, N., M. S. ARAYNE (2007): In vitro activity of cefadroxil, cephalexin, cefatrizine and 
cefpirome in presence of essential and trace elements. Pak. J. Pharm. Sci. 20, 305-310.
Received: 9 December 2010
Accepted: 6 May 2011
________________________________________________________________________________________
RAJPUT, N., V. K. DUMKA, H. S. SANDHU: Kinetika raspodjele cefpiroma i 
njegovo in vitro vezanje na proteine plazme u goveda. Vet. arhiv 82, 1-9, 2012.
SAŽETAK
Istražena je raspodjela cefpiroma i njegovo in vitro vezanje na proteine plazme u petero muške bivolje 
teladi nakon jednokratne intramuskularne primjene u dozi od 10 mg/kg. Koncentracija cefpiroma u plazmi bila 
je procijenjena pomoću mikrobioloških testova. Njegovo vezanje na proteine plazme određeno je za različite 
koncentracije pomoću dijalize. Vršna razina cefpiroma u plazmi nakon intramuskularne primjene postignuta je 
45 minuta nakon davanja, a lijek je u plazmi bio dokazan iznad MIC od 0,5 μg/mL do 10 sati nakon davanja. 
Raspodjela lijeka bila je sukladna modelu otvorenosti jednog odjeljka. Vrijednost t1/2Ka iznosila je 0,21 ± 0,01 h, 
t1/2β 2,06 ± 0,02 h, a AUC 31,7 ± 0,95 μg/mL/h. Cefpirom se vezao na proteine plazme u visini od 26,0 ± 2,84 
% u razmaku koncentracije od 1-100 μg/mL. Sposobnost vezanja cefpiroma na proteine plazme bila je 3,71 
×10-8 ± 0,31 ×10-8 mol/g, a konstanta njegova oslobađanja od kompleksa protein-lijek iznosila je 3,43 ×10-7± 
0,46 ×10-7 mola. 
Ključne riječi: telad, cefpirom, raspodjela, vezanje na proteine________________________________________________________________________________________
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